17474 Federal Register / Vol. 70, No.
65 / Wednesday, April 6, 2005 / Notices
Drug
Glutethimide (2550) ......................
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (non-
dosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Opium powdered (9649) ..............
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
The company plans to import the
listed controlled substances for drug
testing and analysis.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 6, 2005.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c),(d),(e) and (f) are
satisfied.
VerDate jul<14>2003 18:17 Apr 05, 2005 Jkt 205001
Schedule Dated: March 29, 2005.
William J. Walker,
II Deputy Assistant Administrator, Office of
II Diversion Control, Drug Enforcement
II Administration.
II [FR Doc. 05–6792 Filed 4–5–05; 8:45 am]
II
BILLING CODE 4410–09–P
II
II
II
II DEPARTMENT OF JUSTICE
II
II Drug Enforcement Administration
II
II Importer of Controlled Substances;
II Notice of Application
II Pursuant to 21 U.S.C. 958(i), the
II Attorney General shall, prior to issuing
II a registration under this Section to a
II bulk manufacturer of a controlled
II substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on January
26, 2005, Stepan Company, Natural
Products Department, 100 W. Hunter
Avenue, Maywood, New Jersey 07607,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Coca Leaves (9040), a basic class of
controlled substance listed in Schedule
II.
The company plans to import the
listed controlled substance for the
manufacture of bulk controlled
substances and distribution to its
customers.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than (30 days from
publication).
PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 E:\FR\FM\06APN1.SGM
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
Schedule I or II are, and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: March 29, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6801 Filed 4–5–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on February 16,
2005, Varian, Inc., Lake Forest, 25200
Commercentre Drive, Lake Forest,
California 92630–8810, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in Schedules II:
Drug Schedule
Phencyclidine (7471) .................... II
1–Piperidinocyclohexane- II
carbonitrile (8603).
Benzoylecgonine (9180) ............... II
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
06APN1
 Federal Register / Vol. 70, No. 65 / Wednesday, April 6, 2005 / Notices
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than (60 days from
publication).
Dated: March 29, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6796 Filed 4–5–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employee Benefits Security
Administration
Proposed Extension of Information
Collection Request Submitted for
Public Comment and
Recommendations; PTE 86–128
ACTION: Notice.
SUMMARY: The Department of Labor
(Department), as part of its continuing
effort to reduce paperwork and
respondent burden, conducts a
preclearance consultation program to
provide the general public and Federal
agencies with an opportunity to
comment on proposed and continuing
collections of information in accordance
with the Paperwork Reduction Act of
1995 (PRA 95). This program helps to
ensure that requested data can be
provided in the desired format,
reporting burden (time and financial
resources) is minimized, collection
instruments are clearly understood, and
the impact of collection requirements on
respondents can be properly assessed.
Currently, the Employee Benefits
Security Administration is soliciting
comments concerning the proposed
extension of a currently approved
collection of information, Prohibited
Transaction Class Exemption 86–128 for
certain transactions involving employee
benefit plans and securities broker-
dealers.
A copy of the proposed information
collection request (ICR) can be obtained
by contacting the office listed below in
the ADDRESSES section of this notice.
DATES: Written comments must be
submitted to the office listed in the
ADDRESSES section below on or before
June 6, 2005.
ADDRESSES: Interested parties are
invited to submit written comments
regarding the collection of information.
VerDate jul<14>2003 18:17 Apr 05, 2005 Jkt 205001
Send comments to Mr. Gerald B.
Lindrew, Office of Policy and Research,
U.S. Department of Labor, Employee
Benefits Security Administration, 200
Constitution Avenue, NW., Room N–
5647, Washington, DC 20210.
Telephone: (202) 693–8410. Fax: (202)
693–4745 (These are not toll-free
numbers).
SUPPLEMENTARY INFORMATION:
I. Background
Prohibited Transaction Class
Exemption 86–128 permits persons who
serve as fiduciaries for employee benefit
plans to effect or execute securities
transactions on behalf of employee
benefit plans. The exemption also
allows sponsors of pooled separate
accounts and other pooled investment
funds to use their affiliates to effect or
execute securities transactions for such
accounts in order to recapture brokerage
commissions for benefit of employee
benefit plans whose assets are
maintained in pooled separate accounts
managed by the insurance companies.
This exemption provides relief from
certain prohibitions in section 406(b) of
the Employee Retirement Income
Security Act of 1974 (ERISA) and from
the taxes imposed by section 4975(a)
and (b) of the Internal Revenue Code of
1986 (the Code) by reason of Code
section 4975(c)(1)(E) or (F).
In order to insure that the exemption
is not abused, that the rights of
participants and beneficiaries are
protected, and that the exemption’s
conditions are being complied with, the
Department has included in the
exemption five information collection
requirements. The first requirement is
written authorization executed in
advance by an independent fiduciary of
the plan whose assets are involved in
the transaction with the broker-
fiduciary. The second requirement is,
within three months of the
authorization, the broker-fiduciary
furnish the independent fiduciary with
any reasonably available information
necessary for the independent fiduciary
to determine whether an authorization
should be made. The information must
include a copy of the exemption, a form
for termination, and a description of the
broker-fiduciary’s brokerage placement
practices. The third requirement is that
the broker-fiduciary must provide a
termination form to the independent
fiduciary annually so that the
independent fiduciary may terminate
the authorization without penalty to the
plan; failure to return the form
constitutes continuing authorization.
The fourth requirement is for the broker-
fiduciary to report all transactions to the
PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 E:\FR\FM\06APN1.SGM
17475
independent fiduciary, either by
confirmation slips or through quarterly
reports. The fifth requirement calls for
the broker-fiduciary to provide an
annual summary of the transactions.
The annual summary must contain all
security transaction-related charges
incurred by the plan, the brokerage
placement practices, and a portfolio
turnover ratio.
II. Review Focus
The Department is particularly
interested in comments that:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
III. Current Actions
The Department is requesting an
extension of the currently approved ICR
pertaining to Prohibited Transaction
Class Exemption 86–128 for certain
transactions involving employee benefit
plans and securities broker-dealers. The
Department is not proposing or
implementing changes to the existing
ICR at this time.
Agency: Department of Labor,
Employee Benefits Security
Administration.
Title: PTE 86–128 for Certain
Transactions Involving Employee
Benefit Plans and Securities Broker-
Dealers.
Type of Review: Extension of a
currently approved collection.
OMB Numbers: 1210–0059.
Affected Public: Individuals or
households; Business or other for-profit;
Not-for-profit institutions.
Total Respondents: 4,200.
Total Responses: 284,000.
Frequency of Response: Quarterly;
Annually.
Total Annual Burden: 93,530 hours.
Total Annual Cost (Operating &
Maintenance): $183,550.
Comments submitted in response to
this request will be summarized and/or
06APN1